[144] MICRON TECHNOLOGY INC SEC Filing
Rhea-AI Filing Summary
Micron Technology (MU) filed a Form 144 notifying the proposed sale of 15,000 common shares via Merrill Lynch on NASDAQ, with an aggregate market value of $2,460,600. The filing shows 1,119,125,101 shares outstanding, placing the proposed sale at a de minimis fraction of outstanding stock. The shares were acquired through the company's compensation programs: two ESPP purchases (May 2 and Aug 4, 2024) totaling 3,902 shares and stock bonuses from Oct 13, 2023 totaling 11,098 shares.
The filer reports no securities sold in the past three months and indicates payroll or no-payment origins for the listed acquisitions. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Positive
- Transaction fully disclosed with broker, acquisition dates, and payment methods, meeting Rule 144 requirements
- Acquisitions originate from compensation programs (ESPP and stock bonuses), indicating ordinary employee dispositions rather than forced liquidations
- Size is immaterial relative to 1,119,125,101 shares outstanding, suggesting minimal market impact
Negative
- None.
Insights
TL;DR: Routine insider/employee sale notice; size is negligible relative to shares outstanding, so market impact is likely minimal.
The Form 144 discloses an intended sale of 15,000 Micron common shares through a broker on NASDAQ with an indicated aggregate market value of $2.46 million. Acquisition details show employee-related origins (ESPP and stock bonuses) with payment via payroll or no payment required, consistent with compensation vesting and sale of vested shares. No prior sales in the past three months are reported, which reduces concerns about accelerated disposition. Given the outstanding share count of 1.119 billion, the transaction is immaterial to capitalization and unlikely to affect liquidity or valuation.
TL;DR: Filing appears compliant with Rule 144 disclosure requirements; seller attests no undisclosed material information.
The filing provides required broker, acquisition, and payment method details and includes the standard attestation regarding material adverse information and Rule 10b5-1 plan language. There are no reported sales in the preceding three months and acquisition dates are documented, which supports compliance review. The disclosure does not reveal any regulatory or governance concerns based on the information provided.